Adicet Bio, Inc.ACETNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025. “Adicet closed the year with solid momentum, driven by strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the.

defenseworld.net

Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $69.00

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has

defenseworld.net

Adicet Bio, Inc. (NASDAQ:ACET) Receives $69.00 Consensus PT from Brokerages

Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one

businesswire.com

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York. Details of the event are as follows: Date: Thursday, February 12, 2026 Time: 2:00p.m. ET The l.

defenseworld.net

Adicet Bio (NASDAQ:ACET) Shares Pass Below 200-Day Moving Average – What’s Next?

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $11.11 and traded as low as $7.87. Adicet Bio shares last traded at $8.28, with a volume of 137,944 shares. Analyst Upgrades

defenseworld.net

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 95.7% in December

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 642,724 shares, a decline of 95.7% from the December 15th total of 14,910,583 shares. Currently, 7.0% of the shares of the stock are

defenseworld.net

Adicet Bio (NASDAQ:ACET) Stock Passes Below Two Hundred Day Moving Average – Should You Sell?

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $11.22 and traded as low as $8.07. Adicet Bio shares last traded at $8.45, with a volume of 116,371 shares traded. Wall Street Analyst Weigh In Several research

businesswire.com

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2026. “Heading into 2026, we are proud of the strong execution across our pipeline. Since reporting data in October from our prula-cel Phase 1 program in autoimmune diseases, enrollment has more than doubled with.

defenseworld.net

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 14,910,583 shares, a growth of 40.3% from the November 30th total of 10,629,486 shares. Based on an average daily trading volume, of 2,860,587

businesswire.com

Adicet Bio Announces Reverse Stock Split

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet's common stock, par value $0.0001 per share. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a revers.

defenseworld.net

Adicet Bio (NASDAQ:ACET) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.72 and traded as low as $0.4859. Adicet Bio shares last traded at $0.5110, with a volume of 1,385,602 shares traded. Analyst Upgrades and Downgrades Several

businesswire.com

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet's common stock with an exercise price of $0.65 per share, the closing price of.

defenseworld.net

Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.33

Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has

businesswire.com

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2025. “We were pleased to announce positive preliminary data last month from seven SLE and LN patients treated in our Phase 1 trial of ADI-001, underscoring its broad potential as a t.

businesswire.com

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2025. Five individuals were hired by Adicet in October 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 97,200 shares of Adicet's common stock with an exercise price of $0.75 per share,.

businesswire.com

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston. Details of the event are as follows: Date: Tuesday, November 11, 20.

$Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)$

businesswire.com

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA. “Dosing the first patient in our clinical study of ADI-001 in treatment-refractory RA marks an important milestone in our Phase 1 program, which is now en.

seekingalpha.com

Adicet Bio, Inc. - Special Call

Adicet Bio, Inc. - Special Call Company Participants Chen Schor - CEO, President & Director Julie Maltzman - Chief Medical Officer Blake Aftab - Senior VP & Chief Scientific Officer Conference Call Participants Jenna Li - Jefferies LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Karina Rabayeva - Truist Securities, Inc., Research Division John Newman - Canaccord Genuity Corp., Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Robert Burns - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, everyone, and welcome to the Adicet webcast.

benzinga.com

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance